Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Esfini Farahani has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Amos Olalekan Akinyemi

    Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA

    2 shared publications
  • Bolaji Owoyemi

    Department of Pharmacy, Faculty of Pharmaceutical Sciences University of São Paulo São Paulo Brazil

    1 shared publication
  • Chripus Ngule

    Department of Oral Medicine, Infection and Immunity Harvard School of Medicine Boston Massachusetts USA

    1 shared publication
  • Chun Li

    Department of Toxicology and Cancer Biology, College of Medicine University of Kentucky Lexington Kentucky USA

    1 shared publication
  • Fatemeh Seilani

    Department of Toxicology and Cancer Biology, Collage of Medicine, University of Kentucky, Lexington, KY 40536, USA

    1 shared publication
  • Fatemeh Selani

    Department of Toxicology and Cancer Biology, College of Medicine University of Kentucky Lexington Kentucky USA

    1 shared publication

Latest Publications

  • Open Access

    Targeting GRP78 and the Proteostasis Network to Break the Therapeutic Ceiling in Neuroendocrine Prostate Cancer

    by Amos Olalekan Akinyemi, Rakibul Alam, Mithu Howlader, Mohammad Esfini Farahani, Lixiang Gu, Chun Li, Chripus Ngule, Kevin Fulp, Bolaji Owoyemi, Xinyi Wang, et al.

    HSPA5 (also known as GRP78/BiP) is a master regulator of the endoplasmic reticulum (ER) stress response and a key node in the proteostasis network. In neuroendocrine prostate cancer (NEPC), an aggressive, therapy‐refractory lineage that emerges under pressure from androgen receptor (AR) directed therapies, GRP78 is upregulated and co‐opted to maintain malignant cell survival. Beyond its canonical chaperone activity, GRP78 orchestrates adaptive unfolded protein response (UPR) signaling, buffers secretory stress, and stabilizes oncogenic proteomes. These functions collectively allow NEPC cells to evade apoptosis, tolerate proteotoxic stress, and resist next generation therapeutics. This review explores the emerging role of GRP78 as a therapeutic vulnerability in NEPC. We integrate evidence from proteostasis biology, lineage plasticity, and tumor microenvironment remodeling, and highlight experimental and clinical strategies targeting GRP78 directly (e.g., chaperone inhibitors, antibody therapy, peptide displacement) or indirectly through the proteostasis machinery (e.g., ERAD modulators, proteasome inhibitors, and UPR reprogramming). By reframing NEPC not only as a lineage plastic tumor but also as a proteostasis‐addicted state, we propose that GRP78 centered intervention is a promising route to break the current therapeutic ceiling.


  • Endometrial immune profile: A predictor of pregnancy success

    by Sina Baharaghdam, Shima Karimi, Mohammad Esfini Farahani, Leili Aghebati-Maleki, Mehdi Yousefi


  • Open Access

    Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer

    by Mohammad Esfini Farahani, Yanquan Zhang, Amos Olalekan Akinyemi, Fatemeh Seilani, Rakibul Alam, Xiaoqi Liu

    Prostate cancer (PCa) is a highly heterogeneous disease, with castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) representing its most aggressive and therapy-resistant forms. Emerging evidence indicates that lineage plasticity—driven by key transcription factors such as Octamer Binding Factor 4 (OCT4)—plays a crucial role in therapeutic resistance and disease progression. OCT4, in coordination with SOX2 and NANOG, acts as a master regulator of stemness and is frequently upregulated in prostate cancer stem cells (PCSCs). This upregulation contributes to tumor initiation, metastasis, and resistance to both androgen deprivation therapy (ADT) and chemotherapy. In this review, we explore the role of OCT4 in mediating lineage plasticity in prostate cancer, with particular emphasis on its involvement in treatment resistance and neuroendocrine differentiation. We also examine therapeutic strategies aimed at targeting OCT4 directly, such as microRNA-mediated suppression, small-molecule inhibitors, and suicide gene therapy, as well as indirect approaches that modulate OCT4 expression via FGFR and NF-κB signaling pathways. While these strategies offer promising avenues, challenges such as adaptive resistance and the intricate signaling networks within PCSCs remain significant hurdles. A deeper understanding of the molecular mechanisms underlying OCT4-driven plasticity may pave the way for novel therapeutic approaches and improved outcomes in advanced prostate cancer.